
GLP-1 Agonists Show Promise in Treating Patients with MASLD and Diabetes
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
A retrospective cohort study shows that GLP-1 agonists reduced the risk of cirrhosis and HCC in patients with MASLD and Type 2 diabetes.
Dr. Yin Cao’s research links factors such as obesity, metabolic syndrome, prolonged sitting, poor diet and sugar-sweetened beverages with early-onset colorectal cancer.
You don’t build a network by saying no — but you have to follow through, says Dr. Maria Abreu.
The guidelines recommend broad use of rectal NSAIDs to reduce the risk of post-ERCP pancreatitis.